Clinical trial
Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective…
NCT00327379 · Bayer, Industry · Terminated
Key facts
| NCT number | NCT00327379 |
|---|---|
| Title | Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery |
| Official title | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery |
| Lead sponsor | Bayer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Blood Loss, Surgical, Postoperative Hemorrhage |
| Intervention type | Drug |
| Interventions | Trasylol (Aprotinin, BAYA0128), Placebo |
| Enrollment | 54 |
| Start date | Feb 27, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | May 18, 2006 |
| Last update posted | Jun 4, 2019 |
| Countries | Canada, Germany, Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: